Skip to main content

Table 3 Outcome variables (serum) at baseline and the end of treatment

From: N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial

Parameter (mmol/L) Placebo (n = 21) n-3 FA (n = 20) P
Mean ± SD Mean ± SD
TG Baseline 1.61 ± 0.85 1.62 ± 0.60 0.924
8 week 1.66 ± 0.86 1.29 ± 0.37 0.090
% Difference 6.20 ± 10.14* −21.51 ± 12.15*** < 0.001***
TC Baseline 4.97 ± 0.81 4.91 ± 0.72 0.820
8 week 5.05 ± 0.83 4.55 ± 0.65 0.049*
% Difference 2.06 ± 2.97** −6.55 ± 3.59*** < 0.001***
HDL-C Baseline 1.40 ± 0.47 1.34 ± 0.32 0.677
8 week 1.42 ± 0.49 1.37 ± 0.30 0.716
% Difference 2.90 ± 6.73* 1.09 ± 6.97 0.403
Non-HDL-C Baseline 3.55 ± 0.60 3.47 ± 0.59 0.999
8 week 3.62 ± 0.72 3.20 ± 0.54 0.042*
% Difference 4.65 ± 21.00 −9.47 ± 4.58*** 0.007**
LDL-C Baseline 2.61 ± 0.65 2.66 ± 0.61 0.831
8 week 2.64 ± 0.61 2.64 ± 0.55 0.985
% Difference 0.91 ± 4.35 −0.08 ± 5.20 0.510
VLDL-C Baseline 0.93 ± 0.25 0.90 ± 0.29 0.684
8 week 0.98 ± 0.25 0.55 ± 0.20 < 0.001***
% Difference 3.95 ± 9.93 −36.88 ± 11.75*** < 0.001***
LDL-C I Baseline 1.07 ± 0.35 1.03 ± 0.30 0.689
8 week 1.08 ± 0.36 1.03 ± 0.24 0.647
% Difference 1.41 ± 10.21 3.89 ± 15.73 0.551
LDL II Baseline 0.56 ± 0.20 0.63 ± 0.26 0.381
8 week 0.56 ± 0.19 0.67 ± 0.30 0.209
% Difference −0.74 ± 16.24 1.55 ± 17.27 0.664
LDL III
median (Q1, Q3)
Baseline 0.05 (0.02, 0.10) 0.09 (0.05, 0.15) 0.158
8 week 0.05 (0.02, 0.10) 0.02 (0.00, 0.08) 0.090
% Difference 0 (0, 0) −67.5 (−100, −31.25)** < 0.001***
  1. Q1: First quartile, Q3: Third quartile *P < 0.05, ** P < 0.01, *** P < 0.001
  2. P-value represents difference between groups at the relevant timepoint for each parameter. P-value for % difference represents the effect of intervention for that parameter